Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
AVADEL PHARMACEUTICALS PLC (AVDL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AVDL at 56.7/100 on a 32-signal composite quality model, placing it at rank #1,059 of 2,856 stocks — the top half of the AI-ranked universe. Based on the latest XBRL financial filings (Q3 2025), AVADEL PHARMACEUTICALS PLC reports quarterly revenue of $77.5M, net income of $20.0K, an operating margin of 2.5%. AVDL trades on the Nasdaq exchange and files with the SEC under CIK 1012477. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AVDL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AVADEL PHARMACEUTICALS PLC directly from SEC EDGAR.
AI Quality Score
56.7/100
AI Rank
#1,059
Revenue
$77.5M
Net Income
$20.0K
Free Cash Flow
$22.2M
Operating Margin
2.5%
| Period | Form | Revenue | Net income | Operating margin |
|---|---|---|---|---|
| FY 2024 | 10-K | $169.1M | $-48.8M | -25.1% |
| FY 2023 | 10-K | $28.0M | $-160.3M | — |
| FY 2020 | 10-K | $22.3M | $7.0M | 26.0% |
| FY 2019 | 10-K | $59.2M | $-33.2M | -40.7% |
| FY 2018 | 10-K | $103.3M | $-95.3M | -101.6% |
| FY 2017 | 10-K | $173.2M | $68.3M | 51.7% |
| Institution | Shares | Value | Reported |
|---|---|---|---|
| HUNTINGTON NATIONAL BANK | 1 | $16.00 | 2026-06-30 |
13F Pro Quality Score
Rank #1,059 of 2,856 stocksTOP 50%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.